Shares of Aytu BioPharma Inc. (NASDAQ:AYTU – Get Free Report) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.54 and traded as low as $2.03. Aytu BioPharma shares last traded at $2.15, with a volume of 29,458 shares traded.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on AYTU. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Wednesday, April 8th. Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Wall Street Zen raised Aytu BioPharma to a “hold” rating in a research note on Saturday, February 7th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $9.33.
View Our Latest Report on AYTU
Aytu BioPharma Trading Up 2.8%
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). The firm had revenue of $12.41 million during the quarter, compared to analyst estimates of $12.05 million. Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%. As a group, equities analysts expect that Aytu BioPharma Inc. will post -0.69 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aytu BioPharma
Institutional investors and hedge funds have recently modified their holdings of the company. Daytona Street Capital LLC acquired a new stake in shares of Aytu BioPharma in the 4th quarter worth approximately $26,000. Rothschild Wealth LLC purchased a new stake in Aytu BioPharma in the 4th quarter valued at approximately $52,000. Dimensional Fund Advisors LP purchased a new position in Aytu BioPharma during the third quarter worth $58,000. Bellevue Asset Management LLC purchased a new position in Aytu BioPharma during the fourth quarter worth $65,000. Finally, XTX Topco Ltd purchased a new position in Aytu BioPharma during the fourth quarter worth $67,000. Institutional investors and hedge funds own 33.49% of the company’s stock.
About Aytu BioPharma
Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.
Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.
Featured Stories
- Five stocks we like better than Aytu BioPharma
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
